Tscan Therapeutics Stock In The News
| TCRX Stock | USD 4.41 0.41 8.51% |
Our overall analysis of Tscan Therapeutics' news coverage and content from conventional and social sources shows investors' bearish mood towards Tscan Therapeutics. The specific impact of Tscan Therapeutics news on its stock price will depend on a range of factors, including the nature and significance of the news report and investors' perceptions of Tscan Therapeutics' overall financial health and prospects. It also depends on the type and quality of a news publisher.
Some academic researchers believe in a strong correlation between financial news and their impacts on the movements of stock prices. Macroaxis does not take a position on this subject and only provides tools that can help investors to time the market using Tscan Therapeutics headlines in addition to utilizing other, more conventional financial analysis modules. Check out Tscan Therapeutics Backtesting and Tscan Therapeutics Hype Analysis. For more information on how to buy Tscan Stock please use our How to Invest in Tscan Therapeutics guide.
Tscan |
Tscan Therapeutics Today Top News and Investor Outlook
Tscan Therapeutics Past News Timeline
Popular news outlets such as MarketWatch, Bloomberg, or Reuters provide Tscan and other traded companies coverage with news coverage. We help investors stay connected with Tscan headlines for the 17th of November 2024 to make an informed investment decision based on correlating the impacts of news items on Tscan Stock performance. Please note that trading solely based on the Tscan Therapeutics hype is not for everyone as timely availability and quick action are needed to avoid losses.
Tscan Therapeutics stock price changes are notoriously difficult to predict based exclusively on its news coverage or social hype. Still, the Tscan earnings-per-share ratio is a good starting point for gauging a company's future prospects. If a firm's EPS rises and meets or even beats consensus forecasts, its shares stand to increase. However, some very sophisticated investors can spot management manipulation of EPS through actions such as buybacks.
Far too much social signal, news, headlines, and media speculation about Tscan Therapeutics that are available to investors today. That information is available publicly through Tscan media outlets and privately through word of mouth or via Tscan internal channels. However, regardless of the origin, that massive amount of Tscan data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Tscan Therapeutics news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Tscan Therapeutics relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Tscan Therapeutics' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Tscan Therapeutics alpha.
Tscan Largest EPS Surprises
Earnings surprises can significantly impact Tscan Therapeutics' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2024-11-12 | 2024-09-30 | -0.2918 | -0.25 | 0.0418 | 14 | ||
2024-05-13 | 2024-03-31 | -0.26 | -0.32 | -0.06 | 23 | ||
2024-03-06 | 2023-12-31 | -0.29 | -0.21 | 0.08 | 27 | ||
2023-03-08 | 2022-12-31 | -0.7 | -0.78 | -0.08 | 11 | ||
2022-08-10 | 2022-06-30 | -0.75 | -0.63 | 0.12 | 16 | ||
2021-11-10 | 2021-09-30 | -0.64 | -0.8 | -0.16 | 25 |
Tscan Therapeutics Stock Latest Headlines
Some academic researchers believe in a strong correlation between financial news and their impacts on the movements of stock prices. Macroaxis does not take a position on this subject and only provides tools that can help investors to time the market using conventional financial analysis. Below is the latest headlines and news related to Tscan Therapeutics Stock. Current markets are slightly bearish. About 55% of major world exchanges and indexes are down. See today's market update for more information.
15th of November 2024
Significant Stake Acquisition by Biotechnology Value Fund L.P. in TScan Therapeutics Inc at gurufocus.com
13th of November 2024
TScan Therapeutics Receives Buy Rating from Needham Company LLC at thelincolnianonline.com
12th of November 2024
TScan Therapeutics GAAP EPS of -0.25, revenue of 1.04M at seekingalpha.com
6th of November 2024
Coherus BioSciences Reports Q3 Loss, Tops Revenue Estimates at zacks.com
4th of November 2024
Waltham cancer biotech adds to real estate footprint at bizjournals.com
30th of September 2024
TScan Therapeuticss SWOT analysis biotech stock faces pivotal year - Investing.com at news.google.com
29th of August 2024
TScan Therapeutics Director Acquires 18 percent More Stock at simplywall.st
27th of August 2024
TScan therapeutics executive sells over 950k in company stock - Investing.com at news.google.com
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Tscan Therapeutics in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Tscan Therapeutics' short interest history, or implied volatility extrapolated from Tscan Therapeutics options trading.
Additional Tools for Tscan Stock Analysis
When running Tscan Therapeutics' price analysis, check to measure Tscan Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Tscan Therapeutics is operating at the current time. Most of Tscan Therapeutics' value examination focuses on studying past and present price action to predict the probability of Tscan Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Tscan Therapeutics' price. Additionally, you may evaluate how the addition of Tscan Therapeutics to your portfolios can decrease your overall portfolio volatility.